97 related articles for article (PubMed ID: 1419306)
21. A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: results after 5 years of follow-up.
Martelli G; Boracchi P; De Palo M; Pilotti S; Oriana S; Zucali R; Daidone MG; De Palo G
Ann Surg; 2005 Jul; 242(1):1-6; discussion 7-9. PubMed ID: 15973094
[TBL] [Abstract][Full Text] [Related]
22. Conservation treatment intensified with tamoxifen and CAF chemotherapy without axillary dissection for early breast cancer patients with clinically-negative axillary nodes.
Ogawa Y; Nishioka A; Inomata T; Yokota N; Sasaki T; Terashima M; Yoshida S; Tanaka Y; Tohchika N
Oncol Rep; 1999; 6(4):801-5. PubMed ID: 10373660
[TBL] [Abstract][Full Text] [Related]
23. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
24. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.
Overgaard M; Jensen MB; Overgaard J; Hansen PS; Rose C; Andersson M; Kamby C; Kjaer M; Gadeberg CC; Rasmussen BB; Blichert-Toft M; Mouridsen HT
Lancet; 1999 May; 353(9165):1641-8. PubMed ID: 10335782
[TBL] [Abstract][Full Text] [Related]
25. Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: a summary of three randomized trials.
Rutqvist LE; Cedermark B; Glas U; Johansson H; Rotstein S; Skoog L; Somell A; Theve T; Askergren J; Friberg S
Int J Radiat Oncol Biol Phys; 1989 Mar; 16(3):629-39. PubMed ID: 2493433
[TBL] [Abstract][Full Text] [Related]
26. Elderly breast cancer patients treated by conservative surgery alone plus adjuvant tamoxifen: fifteen-year results of a prospective study.
Martelli G; Miceli R; Costa A; Coradini D; Zurrida S; Piromalli D; Vetrella G; Greco M
Cancer; 2008 Feb; 112(3):481-8. PubMed ID: 18098268
[TBL] [Abstract][Full Text] [Related]
27. [Prospective randomized trial on the efficacy of adjuvant endocrine therapy for ER-positive breast cancer patients after radical mastectomy].
Jiang Z; Song S; Liu X
Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):420-2. PubMed ID: 11810777
[TBL] [Abstract][Full Text] [Related]
28. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.
Fisher B; Dignam J; Tan-Chiu E; Anderson S; Fisher ER; Wittliff JL; Wolmark N
J Natl Cancer Inst; 2001 Jan; 93(2):112-20. PubMed ID: 11208880
[TBL] [Abstract][Full Text] [Related]
29. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
30. A 94 year old male stage IV breast cancer patient showing complete remission under tamoxifen treatment after operation.
Tateishi M; Toda T; Minamisono Y; Nagasaki S; Sugimachi K
J Surg Oncol; 1992 Sep; 51(1):71-3. PubMed ID: 1518297
[TBL] [Abstract][Full Text] [Related]
31. The importance of local-regional radiotherapy with conventional or high-dose chemotherapy in the management of breast cancer patients with > or = 10 positive axillary nodes.
Jabro G; Wazer DE; Ruthazer R; Lum R; Sklar N; Goldman D; Enegess D; Erban J
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):273-80. PubMed ID: 10760419
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
33. [Cox proportion hazard model multivariate analysis of prognosis of 1,484 axillary node-negative breast cancer patients].
Shen K; Shen Z; Han Q
Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):221-4. PubMed ID: 10920903
[TBL] [Abstract][Full Text] [Related]
34. Extracapsular axillary node extension in patients receiving adjuvant systemic therapy: an indication for radiotherapy?
Fisher BJ; Perera FE; Cooke AL; Opeitum A; Dar AR; Venkatesan VM; Stitt L; Radwan JS
Int J Radiat Oncol Biol Phys; 1997 Jun; 38(3):551-9. PubMed ID: 9231679
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
[TBL] [Abstract][Full Text] [Related]
36. Randomized trial of adjuvant tamoxifen combined with postoperative radiation therapy or adjuvant chemotherapy in postmenopausal breast cancer.
Rutqvist LE; Cedermark B; Glas U; Johansson H; Rotstein S; Skoog L; Somell A; Theve T; Wilking N; Askergren J
Cancer; 1990 Jul; 66(1):89-96. PubMed ID: 2191764
[TBL] [Abstract][Full Text] [Related]
37. Radiotherapy and tamoxifen after mastectomy in postmenopausal women -- 20 year follow-up of the South Sweden Breast Cancer Group randomised trial SSBCG II:I.
Killander F; Anderson H; Rydén S; Möller T; Aspegren K; Ceberg J; Danewid C; Malmström P
Eur J Cancer; 2007 Sep; 43(14):2100-8. PubMed ID: 17644330
[TBL] [Abstract][Full Text] [Related]
38. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
39. Optimal management of ductal carcinoma in situ of the breast.
Sakorafas GH; Farley DR
Surg Oncol; 2003 Dec; 12(4):221-40. PubMed ID: 14998563
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant therapy for node-negative breast cancer: a cautious interpretation.
Henderson IC
Important Adv Oncol; 1990; ():199-216. PubMed ID: 1691137
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
